Show simple item record

dc.contributor.authorShitara, K
dc.contributor.authorVan Cutsem, E
dc.contributor.authorBang, YJ
dc.contributor.authorFuchs, CS
dc.contributor.authorWyrwicz, L
dc.contributor.authorLee, KW
dc.contributor.authorKudaba, I
dc.contributor.authorGarrido, M
dc.contributor.authorChung, HC
dc.contributor.authorCastro, HR
dc.contributor.authorMansoor, Was
dc.contributor.authorBraghiroli, MIFM
dc.contributor.authorGoekkurt, E
dc.contributor.authorChao, J
dc.contributor.authorWainberg, ZA
dc.contributor.authorKher, U
dc.contributor.authorShah, S
dc.contributor.authorKang, SP
dc.contributor.authorTabernero, J
dc.date.accessioned2019-12-09T17:23:32Z
dc.date.available2019-12-09T17:23:32Z
dc.date.issued2019en
dc.identifier.citationShitara K, Van Cutsem E, Bang YJ, Fuchs CS, Wyrwicz L, Lee KW, et al. LBA44Pembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062. Annals of Oncology. 2019;30(Supplement_5):878.en
dc.identifier.doi10.1093/annonc/mdz394.035en
dc.identifier.urihttp://hdl.handle.net/10541/622598
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdz394.035en
dc.titlePembrolizumab with or without chemotherapy vs chemotherapy in patients with advanced G/GEJ cancer (GC) including outcomes according to Microsatellite Instability-High (MSI-H) status in KEYNOTE-062en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japanen
dc.identifier.journalAnnals of Oncologyen
refterms.dateFOA2020-01-21T20:24:16Z


Files in this item

Thumbnail
Name:
mdz394.035.pdf
Size:
87.48Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract

This item appears in the following Collection(s)

Show simple item record